New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Merck will showcase results in innovative solutions in HIV treatment and prevention
Several technologies for hemoglobinopathies are being transferred to commercial partners
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
